Skip to content

8-KAccepted Apr 30, 8:04 AM ET

Alnylam Pharmaceuticals Reports Q1 2026 Financial Results

ALNYALNYLAM PHARMACEUTICALS, INC.

Accepted (ET)

8:04 AM

Apr 30, 2026

Filed

Apr 30, 2026

Documents

13

Size

479.3 KB

Summary

Alnylam Pharmaceuticals Reports Q1 2026 Financial Results

Updated

What Happened
Alnylam Pharmaceuticals, Inc. (ALNY) announced its financial results for the quarter ended March 31, 2026 and furnished a related press release on April 30, 2026. The company filed a Current Report on Form 8-K to disclose the quarterly results under Item 2.02 (Results of Operations and Financial Condition).

Key Details

  • 8-K filed on April 30, 2026 reporting quarterly results for the period ended March 31, 2026.
  • The full text of the press release with the results is furnished as Exhibit 99.1 to the 8-K.
  • Reported Items on the 8-K: Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).
  • Ticker: ALNY (Nasdaq).

Why It Matters
This filing notifies investors that Alnylam has released its latest quarterly earnings and related financial information. Retail investors should review the Exhibit 99.1 press release for specific metrics—revenue, earnings (loss or profit), cash flow, and any management commentary or guidance—that could affect the stock price or investment thesis.

AI-written summary · check the filing